21 February 2024
Cambridge Cognition Holdings plc
("Cambridge Cognition", the "Company" or the "Group")
Cambridge Cognition and ActiGraph Announce Partnership to Accelerate Adoption of Digital Measurements for Central Nervous System Trials
Cambridge Cognition Holdings plc (AIM: COG), which develops and markets digital solutions to assess brain health, is pleased to announce a new strategic partnership with ActiGraph, a leading provider of wearable technologies for clinical trials. The partnership will deliver a broad suite of assessments to provide a fully rounded view of mental and physical capabilities. With both companies holding leading positions in their respective markets, it is anticipated that the co-promotion planned under the agreement will support growth in market share in the future.
ActiGraph's AccelerantTM partnership program is designed to advance the use of digital health technologies (DHTs) in clinical development by simplifying CROs' and technology vendors' access to raw data streams. As part of this strategic partnership, Cambridge Cognition and ActiGraph will combine their collective expertise in digital data collection to enhance assessment capabilities in CNS trials in areas where there is a large unmet need, such as schizophrenia and dementia.
Cambridge Cognition offers accurate and sensitive touch-screen and voice-based digital assessments of cognition and other brain health indicators that have been based on over 30 years of innovation and scientific validation. The Company's suite of e-clinical technology solutions can be used at home or in-clinic, giving pharmaceutical companies and research institutions flexibility to reliably capture a broad range of important clinical measures.
As well as being leaders in the collection of clinical insights for clinical trials, both companies also lead in providing solutions for academic researchers, enabling hundreds of research projects each year. The companies' technologies have been used together by top 20 pharmaceutical companies in clinical trials already. The combination of actigraphy data and brain health assessments may enable more accurate multi-modal digital biomarkers in the future.
Francesca Cormack, Chief Scientist, Cambridge Cognition, commented:
"CNS disorders are characterised by a host of heterogeneous symptoms which impact daily life, but that are often inadequately addressed by existing treatments. Our partnership with ActiGraph represents an exciting combination of expertise in objective digital measures of actigraphy, speech and cognition that will help accelerate the development of treatments for patients and improve efficiency in clinical trials."
Christine Guo, Chief Scientific Officer, ActiGraph, commented:
"Digital health technologies give us the ability to collect data objectively during a patient's everyday life. This is especially important in CNS disorders where conventional assessments are prone to subjective biases. We are excited about this partnership with Cambridge Cognition to provide advanced clinical insights to study teams conducting CNS trials."
Enquiries:
| |
Notes to Editors
About Cambridge Cognition
Cambridge Cognition is a technology company developing digital health products to better understand, detect and treat conditions affecting brain health. The Company's software products assess cognitive health, speech and language and other specialist measurements in patients worldwide to improve clinical trial outcomes, identify and stratify patients early and improve global efficiency in pharmaceutical and healthcare industries.
For further information visit www.cambridgecognition.com
About ActiGraph
ActiGraph is pioneering the digital transformation of clinical research. We provide end-to-end digital health technology (DHT) solutions by integrating and operationalizing the best hardware, software, and algorithms to generate reliable evidence and get the right treatments to the right patients, faster. ActiGraph's medical-grade wearable technology platform has been used to capture real-world, continuous digital measures of activity, sleep, and mobility for nearly 250 industry-sponsored clinical trials and thousands of academic research studies. Appearing in over 23,000 published scientific papers to date, ActiGraph is the most experienced and trusted wearable technology partner in the industry.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.